Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation
复制标题
DOI：
10.1111/j.1365-2036.2008.03629.x
复制
发表时间：
2008-04-15
影响因子：
7.6
通讯作者：
Ueno, R.
中科院分区：
文献类型：
--
作者：
Johanson, J. F.;Drossman, D. A.;Ueno, R.
对便秘患者的试验分析表明，鲁比前列酮可能是治疗肠易激综合征伴便秘的有效方法。目的评估三种鲁比前列酮剂量治疗肠易激综合征伴便秘的有效性和安全性。方法195例肠易激综合征伴便秘患者接受16 [8 μ g，每日两次（b.d.）]，32（16 μ g b.d.）或48 μ g（24 μ g b.d.）鲁比前列酮或安慰剂b.d. 3个月胃肠道参数记录在日记每天patients.Results1个月后，鲁比前列酮显示出显着更大的改善，平均腹部不适/疼痛评分与安慰剂（P = 0.023）。2个月后，所有鲁比前列酮组的平均腹部不适/疼痛评分均显著改善（P
BackgroundAnalyses of a trial in constipated patients indicated that lubiprostone may be an effective treatment for irritable bowel syndrome with constipation.AimTo assess the efficacy and safety of three lubiprostone doses for irritable bowel syndrome with constipation.Methods195 irritable bowel syndrome with constipation patients received daily doses of 16 [8 mu g twice daily (b.d.)], 32 (16 mu g b.d.) or 48 mu g (24 mu g b.d.) lubiprostone or placebo b.d. for 3 months. Gastrointestinal parameters were recorded in diaries daily by patients.ResultsAfter 1 month, lubiprostone showed significantly greater improvements in mean abdominal discomfort/pain scores vs. placebo (P = 0.023). After 2 months, all lubiprostone groups showed significantly greater improvements in mean abdominal discomfort/pain scores (P